OTEZLA offers convenient, oral dosing1
Treatment begins with a 5-day titration1:
After the titration period, the maintenance dose of OTEZLA is 30 mg twice daily for most patients1
The dose of OTEZLA should be reduced to 30 mg once daily in patients with severe renal impairment1*:
*Creatinine clearance (CrCl) <30 mL/min estimated by the Cockcroft-Gault equation.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).